Clene Inc. to Showcase Innovations at Canaccord 45th Annual Growth Conference

Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company at the forefront of developing treatments for neurodegenerative diseases such as ALS and MS, has announced its management team will present at the Canaccord 45th Annual Growth Conference. This participation underscores the company's commitment to advancing its innovative therapies and engaging with the investment community to discuss its progress and future directions.

The conference, known for bringing together leading growth companies and investors, provides a platform for Clene to showcase its investigational therapy, CNM-Au8(R). This first-in-class therapy is designed to improve the survival and function of central nervous system cells by targeting mitochondrial function and the NAD pathway, while also reducing oxidative stress. The potential impact of CNM-Au8(R) on patients with neurodegenerative diseases could be significant, offering hope where treatment options are currently limited.

Investors and industry watchers keen on following Clene's developments can find more information in the company's newsroom at https://ibn.fm/CLNN. The presentation at the Canaccord conference represents a pivotal moment for Clene as it seeks to broaden awareness of its research and therapeutic solutions among potential investors and partners.

Clene's focus on neurodegenerative diseases addresses a critical unmet medical need. With conditions like ALS, Parkinson’s disease, and multiple sclerosis affecting millions worldwide, the company's work could have far-reaching implications for patients and the broader healthcare landscape. The participation in the Canaccord 45th Annual Growth Conference is a testament to Clene's dedication to innovation and its potential to make a meaningful difference in the lives of those affected by these challenging conditions.